ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,062.00
-0.10%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36125
0.00%
Bitcoin
67,261.69
0.48%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Mustang Bio Inc (MBIO)

  7. Mustang Bio Inc (MBIO) News

MBIO

Mustang Bio (MBIO)

Mustang Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MBIO
DateTimeSourceHeadlineSymbolCompany
05/13/20245:01AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
05/02/20243:01PMGlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
04/29/20247:00PMGlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
03/28/20248:00AMGlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
03/11/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
03/11/20243:05PMGlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
03/11/20243:02PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
03/07/20246:30AMGlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
02/14/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
01/25/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
01/11/20247:30AMGlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
01/04/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
12/19/20233:06PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
12/11/20238:52PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
12/11/20237:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
12/11/20237:30AMGlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
11/14/20233:44PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
11/14/20233:05PMGlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
11/03/20232:22PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MBIOMustang Bio Inc
11/02/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
11/02/20238:28AMGlobeNewswire Inc.Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
10/30/20231:57PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
10/30/20231:15PMGlobeNewswire Inc.Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
10/30/20239:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
10/26/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
10/26/202311:30AMGlobeNewswire Inc.Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
10/26/20238:00AMGlobeNewswire Inc.Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaNASDAQ:MBIOMustang Bio Inc
10/04/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
08/16/20237:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
08/14/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
 Showing the most relevant articles for your search:NASDAQ:MBIO

Your Recent History

BIT
Q00120
Leonteq Securities
USOTC
LEIC
Lead Innovation (PK)
LSE
VD84
Citi Fun 25
LSE
57CR
Cred Ag Co 29
LSE
0QDB
Voxel
GDAX
ACSUSD
Access Protocol
NYSE
PSB-I.CL
AMEX
RZV
Invesco S&P SmallCap 600...
COIN
BIKBTC
COIN
RAKUSD
Rake Finance
ASX
ECSDA
MRTX
CFDBTC
COIN
HSNBTC
Helper Search Token
BMF
RTFTSBR
RTFTSBR
ASX
ARXNA
COIN
HEROGBP
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved